Zafar Malik

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

Nicholas D. James, Johann S. de Bono, Melissa Spears et al. · New England Journal of Medicine · 2017 · 1.8K citations · Full text

Medicine, Oncology, Urology +14

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

David P. Dearnaley, Isabel Syndikus, Helen Mossop et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Christopher Parker, Nicholas D. James, Chris Brawley et al. · The Lancet · 2018 · 1.3K citations · Full text

Medicine, Oncology, Urology +13

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

N.W. Clarke, Amin Ali, Fiona C. Ingleby et al. · Annals of Oncology · 2019 · 398 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17